Relationship between genetic polymorphisms of CYP1A1, NQO1 and EPHX1 and susceptibility to bladder cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 20, Issue 1, 2013, Pages 10-14

  Fu, Jing ^a   Chen, Bi Cheng ^b  

^a Shaoxing Second Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bladder neoplasms; Cytochrome P450; Epoxide hydrolase; NAD(P)H: quinone oxidoreductase 1; Polymorphism, genetics

Indexed keywords

CYTOCHROME P450 1A1; EPHX1 PROTEIN; NQ01 PROTEIN; PRIMER DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84886893527     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Giannakopoulos X, Charalabopoulos K, Baltogiannis D, et al. The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer [J]. Anticancer Res, 2002, 22(6B): 3801-3804.
2. Chao C, Zhang ZF, Berthiller J, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(5): 979-987.
3. Pandith AA, Khan NP, Shah ZA, et al. Association of bladder cancer risk with an NAD(P)H: quinone oxidoreductase polymorphism in an ethnic Kashmiri population [J]. Biochem Genet, 2011, 49(7-8): 417-426.
4. Figueroa JD, Malats N, García-Closas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes [J]. Carcinogenesis, 2008, 29(10): 1955-1962.
5. Brockmöller J, Cascorbi I, Kerb R, et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk [J]. Cancer Res, 1996, 56(17): 3915-3925.
6. Öztürk T, Kahramanö T, Toptaş B, et al. The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population [J]. In Vivo, 2011, 25(4): 663-668.
7. 2007, 2(26): 3-5.
8. Hamajima N, Saito T, Matsuo K, et al. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping [J]. Cancer Res, 2000, 91(9): 865-868.
9. 2010, 17(17): 1325-1327.
10. 2006, 13(22): 1686-1688.
11. 2004, 25(4): 355-358.
12. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci [J]. Cell Res, 2005, 15(2): 97-98.
13. Nioi P, Hayes JD. Contribution of NAD(P)H: quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors [J]. Mutat Res, 2004, 555(1-2): 149-171.
14. 2009, 18(11): 828-831.
15. Srivastava DS, Mandhani A, Mittal RD. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India [J]. Arch Toxicol, 2008, 82(9): 633-639.